Transrectal Sonography in Prostate Evaluation

Radiologic Clinics of North America

Volumn 44, Issue 5, 2006, Pages 679-687

  Boczko, Judd ^a   Messing, Edward ^a   Dogra, Vikram ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPICILLIN; ANTIBIOTIC AGENT; GENTAMICIN; PENICILLIN G; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; VANCOMYCIN; WARFARIN;

ANATOMY; ANESTHESIA; ANTIBIOTIC PROPHYLAXIS; ARTERIAL CIRCULATION; CANCER DIAGNOSIS; DIAGNOSTIC PROCEDURE; DOPPLER FLOWMETRY; ECHOGRAPHY; EJACULATORY DUCT; EMBRYOLOGY; HUMAN; INFECTION; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL MICROWAVE THERMOTHERAPY;

BIOPSY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33749356144     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2006.07.001     Document Type: Review

References (54)

1. Watanabe H., Igari D., Tanahashi Y., et al. Measurements of size and weight of prostate by means of transrectal ultrasonotomography. Tohoku J Exp Med 114 (1974) 277-285
2. Watanabe H., Igari D., Tanahashi Y., et al. Transrectal ultrasonotomography of the prostate. J Urol 114 (1975) 734-739
3. Watanabe H., Igari D., Tanahashi Y., et al. An evaluation of the function of new special equipment for transrectal ultrasonotomography. Tohoku J Exp Med 118 (1976) 387-392
4. Kirby R., McConnell J.D., Fitzpatrick J.M., et al. Textbook of benign prostatic hyperplasia (1996), Oxford University Press, Oxford, UK
5. Walsh P. Campbell's urology. 8th edition (2002), Saunders, Philadelphia
6. McNeal J.E., Redwine E.A., Freiha F.S., et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 12 (1988) 897-906
7. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173 (2005) 1256-1261
8. McNeal J.E. The prostate gland: morphology and pathobiology. Monogr Urol 4 (1983) 3-33
9. Lepor H., Nieder A., Feser J., et al. Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical BPH. J Urol 158 (1997) 85-88
10. de la Rosette J.J., van der Schoot D.K., and Debruyne F.M. Recent developments in guidelines on benign prostatic hyperplasia. Curr Opin Urol 12 (2002) 3-6
11. AUA Practice Guidelines Committee. AUA guideline on management of BPH (2003). Diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
12. Beckman T.J., and Mynderse L.A. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 80 (2005) 1356-1362
13. McConnell JD, Roehrborn CG, Bautista OM, et al, of the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: the long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med 2003;349:2387-98.
14. Tam P.C. Transurethral resection of the prostate: reaffirming the gold standard. Hong Kong Med J 11 (2005) 79-84
15. Gordon N.S., Hadlow G., Knight E., et al. Transurethral resection of the prostate: still the gold standard. Aust N Z J Surg 67 (1997) 354-357
16. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
17. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
18. Paquette E.L., Sun L., Paquette L.R., et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 60 (2002) 756-759
19. Bauer J.J., Zeng J., Zhang W., et al. Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer. Prostate Cancer Prostatic Dis 3 (2000) 43-46
20. Terris M.K. Prostate biopsy strategies: past, present, and future. Urol Clin North Am 29 (2002) 205-212
21. Richie J.P., Catalona W.J., Ahmann F.R., et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urol 42 (1993) 365-374
22. Wang M.C., Valenzuela L.A., Murphy G.P., et al. Purification of a human prostate specific antigen. Invest Urol 17 2 (1979) 159-163
23. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76 5 (1985) 1899-1903
24. Christensson A., Laurell C.B., and Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 194 3 (1990) 755-763
25. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng/ml. N Engl J Med 350 (2004) 2239-2246
26. Carter H.B., Pearson J.D., Metter J.E., et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
27. Seaman E., Whang M., Olsson C.A., et al. Prostate-specific antigen density: role in patient evaluation and management. Urol Clin North Am 20 (1993) 653-663
28. Christensson A., Bjork T., Nilsson O., et al. Serum PSA complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
29. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
30. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-PSA preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml PSA. J Urol 171 (2004) 2239-2244
31. Herget E., Saliken J., Donnelly B., et al. Transrectal ultrasound guided biopsy of the prostate: relation between ASA use and bleeding complications. Can Assoc Radiol J 50 (1999) 173-176
32. Bonow R.O., Carabello B., de Leon A.C., et al. ACC/AHA guidelines for the management of patients with valvular heart disease. J Heart Valve Dis 7 (1998) 672-707
33. Davis M., Sofer M., Kim S.S., et al. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol 167 (2002) 566-570
34. Carey J.M., and Korman J.H. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications?. J Urol 166 (2001) 82-85
35. Vallancien G., Prapotnich D., Veillon B., et al. Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol 146 (1991) 1308-1312
36. Gordon P.H. Anorectal anatomy and physiology. Gastroenterol Clin North Am 30 (2001) 1-13
37. Shinohara K., Wheeler T.M., and Scardino P.T. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 142 1 (1989) 76-82
38. Brawer M.K., Deering R.E., Brown M., et al. Predictor of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 73 (1994) 678-687
39. Newman J.S., Bree R.L., and Rubin J.M. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 195 (1995) 86-90
40. Patel U., and Rickards D. The diagnostic value of color Doppler flow in the peripheral zone of the prostate, with histologic correlation. Br J Urol 74 (1994) 590-595
41. Arger P.H., Malkowicz B., VanArsdalen K.N., et al. Color and power Doppler sonography in the diagnosis of prostate cancer. J Ultrasound Med 23 (2004) 623-630
42. Pelzer A., Bektic J., Berger A.P., et al. Prostate cancer detection in men with PSA 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173 (2005) 1926-1929
43. Ragde H., Kenny G.M., Murphy G.P., et al. Transrectal ultrasound microbubble contrast angiography of the prostate. Prostate 32 (1997) 279-283
44. Karaman C.Z., Unsal A., Akdilli A., et al. The value of contrast enhanced power Doppler ultrasonography in differentiating hypoechoic lesions in the peripheral zone of prostate. Eur J Radiol 54 (2005) 148-155
45. Nash P., Bruce J., Indudhara R., et al. Transrectal ultrasound guided prostatic nerve blockade eases systemic needle biopsy of the prostate. J Urol 155 (1996) 607-609
46. Hodge K.K., McNeal J.E., Terris M.K., et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 1 (1989) 71-74
47. Keetch D.W., Catalona W.J., and Smith D.S. Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol 151 6 (1994) 1571-1574
48. Bauer J.J., Zeng J., Weir J., et al. 3D computer simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. Urology 53 5 (1999) 961-967
49. Chen M.E., Troncoso P., Johnston D.A., et al. Optimization of prostate biopsy strategy using computer based analysis. J Urol 158 6 (1997) 2168-2175
50. Ravery V., Goldblatt L., Royer B., et al. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 164 2 (2000) 393-396
51. Norberg M., Egevad L., Holmberg L., et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50 4 (1997) 562-566
52. Epstein J.I., Walsh P.C., and Carter H.B. Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57 (2001) 1112-1116
53. Naughton C.K., Miller D.C., Mager D.E., et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 164 (2000) 388
54. Jones J.S., Oder M., and Zippe C.D. Saturation prostate biopsy with periprostatic block can be performed in the office. J Urol 168 5 (2002) 2108-2119